• Molecular NameOrlistat
  • Synonym(-)-Tetrahydrolipstatin; Orlipastat; Orlipastatum [INN-Latin]; orlistat; Tetrahydrolipstatin
  • Weight495.745
  • Drugbank_IDDB01083
  • ACS_NO96829-58-2
  • Show 3D model
  • LogP (experiment)8.533
  • LogP (predicted, AB/LogP v2.0)9.01
  • pkaN/A
  • LogD (pH=7, predicted)9.01
  • Solubility (experiment)Insoluble
  • LogS (predicted, ACD/Labs)(ph=7)-7.53
  • LogSw (predicted, AB/LogsW2.0)0.0
  • Sw (mg/ml) (predicted, ACD/Labs)0.0
  • No.of HBond Donors1
  • No.of HBond Acceptors6
  • No.of Rotatable Bonds23
  • TPSA81.7
  • StatusFDA approved
  • AdministrationN/A
  • PharmacologyA drug designed to treat obesity.
  • Absorption_valueN/A
  • Absorption (description)N/A
  • Caco_2N/A
  • Bioavailability1.0
  • Protein binding99.0
  • Volume of distribution (VD)N/A
  • Blood/Plasma Partitioning ratio (D_blood)N/A
  • MetabollsmIn the GI tract
  • Half life1~2 h for the parent drug; for the metabolites approx. 2 h for M1 and 13.5 h for M3.
  • ExcretionFecal
  • Urinary ExcretionN/A
  • CleranceN/A
  • ToxicityN/A
  • LD50 (rat)N/A
  • LD50 (mouse)N/A